Cardinal Health elects Robert Azelby to Board of Directors, effective March 1, 2024

CARDINAL HEALTH INC

Robert W. Azelby elected as an independent director, effective March 1, 2024.
Azelby brings over 30 years of biopharma, oncology, and specialty industry experience, including CEO roles.
He will serve on the Board's Risk Oversight Committee and receive standard non-employee director compensation.
Azelby currently serves on boards of ADC Therapeutics and Autolus Therapeutics; former CEO of Eliem Therapeutics and Alder BioPharmaceuticals.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert W. Azelby

Director

CAH · CARDINAL HEALTH INC

Effective: 2024-03-01
Filed: February 28, 2024, 6:59 PM ET

On February 28, 2024, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Azelby to the Board, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation, removal from office, or death.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert W. Azelby was elected as Director at CARDINAL HEALTH INC.

Action: elected
Role: Director

Exact text from the filing

On February 28, 2024, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Azelby to the Board, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation, removal from office, or death.

View on SEC.gov

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0000721371-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.